uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
Show others and affiliations
2014 (English)In: Advances in Therapy, ISSN 0741-238X, E-ISSN 1865-8652, Vol. 31, no 4, 375-391 p.Article, review/survey (Refereed) Published
Abstract [en]

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastrointestinal and skin-related adverse events (AEs). This review summarizes recommendations based on existing guidelines, research evidence, and consensus opinions of expert authors, with the aim of providing practicing physicians with the specific clinical information needed to educate the patient and better manage pirfenidone-related AEs with continued pirfenidone treatment. The main recommendations to help prevent and/or mitigate gastrointestinal and skin-related AEs include taking pirfenidone during (or after) a meal, avoiding sun exposure, wearing protective clothing, and applying a broad-spectrum sunscreen with high ultraviolet (UV) A and UVB protection. These measures can help optimize AE management, which is key to maintaining patients on an optimal treatment dose.

Place, publisher, year, edition, pages
2014. Vol. 31, no 4, 375-391 p.
Keyword [en]
Adverse event management, Expert opinion, Gastrointestinal events, Idiopathic pulmonary fibrosis, Photosensitivity, Pirfenidone, Respiratory, Safety, Skin-related events
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-228237DOI: 10.1007/s12325-014-0112-1ISI: 000335309800001OAI: oai:DiVA.org:uu-228237DiVA: diva2:733282
Note

Correction in: Advances in Therapy, Volume 31, Issue 5, pp 575-576 , doi: 10.1007/s12325-014-0118-8

Available from: 2014-07-08 Created: 2014-07-08 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

fulltext(1272 kB)102 downloads
File information
File name FULLTEXT01.pdfFile size 1272 kBChecksum SHA-512
48245643cadbb8281398c433732d90adc79990cdd375cd27efecb73e4bbaa2a45d1b4960bad1b18619b7123d56e5a96bd0c1a23976d5f0b126296f939cd7fed0
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Hellström, Per M.

Search in DiVA

By author/editor
Hellström, Per M.
By organisation
Gastroenterology/Hepatology
In the same journal
Advances in Therapy
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 102 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 385 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf